TidBiotech

TidBiotech is a South Korean biotechnology company specializing in the development of next-generation drug delivery systems, particularly focusing on stimuli-responsive nanocarriers. The company's core technology enables targeted delivery of various therapeutic payloads, including mRNA, siRNA, and small molecules, by leveraging specific characteristics of the tumor microenvironment such as pH and enzyme activity. TidBiotech's platform is designed to overcome the limitations of conventional lipid nanoparticles, such as systemic toxicity and off-target effects, to improve the safety and efficacy of cancer treatments and gene therapies. The company is currently advancing a pipeline of preclinical programs targeting solid tumors and rare genetic disorders through its proprietary ionizable lipid technologies.